Icotrokinra vs Splenopentin
Overview
Icotrokinra and Splenopentin are both immune support peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Icotrokinra and Splenopentin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Splenopentin | |
|---|---|---|
| Category | Immune Support | Immune Support |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | — | 1-5 mg |
| Frequency | — | as needed |
| Reported benefits | — | Immune modulation, anti-inflammatory, autoimmune support |
| Reported side effects | — | Well-tolerated |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Splenopentin falls under Immune Support. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Icotrokinra: FDA-approved. Splenopentin: not FDA-approved; treated as a research compound.
Dosing. Typical dosing for Icotrokinra is not catalogued. Splenopentin is typically dosed at 1-5 mg (as needed).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Splenopentin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Splenopentin?
- Icotrokinra and Splenopentin are both immune support peptides, but they differ in mechanism, dosing, and regulatory status. Icotrokinra is FDA-approved for one or more indications, whereas Splenopentin is not FDA-approved; generally classified as a research compound.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Splenopentin used for?
- Spleen-derived immune peptide.
- Can you take Icotrokinra and Splenopentin together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Splenopentin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Splenopentin FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Splenopentin is not FDA-approved; generally classified as a research compound.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Splenopentin — full monograph: mechanism, research, dosing & references